IL323508A - שיטות ושימושים לטיפול בבחילות והקאות - Google Patents

שיטות ושימושים לטיפול בבחילות והקאות

Info

Publication number
IL323508A
IL323508A IL323508A IL32350825A IL323508A IL 323508 A IL323508 A IL 323508A IL 323508 A IL323508 A IL 323508A IL 32350825 A IL32350825 A IL 32350825A IL 323508 A IL323508 A IL 323508A
Authority
IL
Israel
Prior art keywords
seq
receptor agonist
agonist peptide
gip receptor
peptide
Prior art date
Application number
IL323508A
Other languages
English (en)
Inventor
Paul Joseph Emmerson
Kieren James Mather
Edward John Pratt
William Christopher Roell
Ricardo J Samms
Shweta Urva
Original Assignee
Lilly Co Eli
Paul Joseph Emmerson
Kieren James Mather
Edward John Pratt
William Christopher Roell
Ricardo J Samms
Shweta Urva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Paul Joseph Emmerson, Kieren James Mather, Edward John Pratt, William Christopher Roell, Ricardo J Samms, Shweta Urva filed Critical Lilly Co Eli
Publication of IL323508A publication Critical patent/IL323508A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL323508A 2023-03-31 2025-09-21 שיטות ושימושים לטיפול בבחילות והקאות IL323508A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363493384P 2023-03-31 2023-03-31
US202363585493P 2023-09-26 2023-09-26
PCT/US2024/022122 WO2024206740A1 (en) 2023-03-31 2024-03-29 Methods and uses for treating nausea and emesis

Publications (1)

Publication Number Publication Date
IL323508A true IL323508A (he) 2025-11-01

Family

ID=90829418

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323508A IL323508A (he) 2023-03-31 2025-09-21 שיטות ושימושים לטיפול בבחילות והקאות

Country Status (9)

Country Link
EP (1) EP4687946A1 (he)
JP (1) JP2026511611A (he)
KR (1) KR20250164847A (he)
CN (1) CN121152634A (he)
AU (1) AU2024246525A1 (he)
IL (1) IL323508A (he)
MX (1) MX2025011529A (he)
TW (1) TW202506169A (he)
WO (1) WO2024206740A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120478382B (zh) * 2025-06-12 2026-06-12 西南医科大学 氯法拉滨在肥胖治疗中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856768A2 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr

Also Published As

Publication number Publication date
EP4687946A1 (en) 2026-02-11
AU2024246525A1 (en) 2025-11-13
TW202506169A (zh) 2025-02-16
CN121152634A (zh) 2025-12-16
WO2024206740A1 (en) 2024-10-03
JP2026511611A (ja) 2026-04-14
MX2025011529A (es) 2025-11-03
KR20250164847A (ko) 2025-11-25

Similar Documents

Publication Publication Date Title
US12616740B2 (en) Methods of using a GIP/GLP1 co-agonist for therapy
CN103338790B (zh) 用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物
BR112015001593B1 (pt) Formulação líquida de uma combinação de insulina e de peptídeo insulinotrópico de longa duração e método para a preparação da dita formulação líquida
AU2025220813A1 (en) Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
TW201305196A (zh) 包含長效胰島素接合物與長效促胰島素肽接合物之用以治療糖尿病之組成物
EP3541366A1 (en) Buffered formulations of exendin (9-39)
JP2024521398A (ja) 肥満及び肥満関連障害の治療
EP4371577A1 (en) Composition for orally administered formulation containing glp-1 analogue
CN107847565A (zh) 用于肌肉减少症治疗的包括胰高血糖素样肽‑1 受体激动剂的药物组合物
WO2023231730A2 (zh) 使用mazdutide的治疗方法
AU2024246525A1 (en) Methods and uses for treating nausea and emesis
JP2023510609A (ja) Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法
BR112020018362A2 (pt) Composição de glp-1 para tratar obesidade e controle de peso
CN115397455A (zh) Glp-1给药方案
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
Johns et al. Future Antidiabetic Drugs
RU2834226C2 (ru) Композиция glp-1 для лечения ожирения и регулирования веса
WO2025259957A1 (en) Compositions and methods for improving insulin sensitivity
HK40094446A (en) Glp-1 dosing regimen
Johns and et al. Future Antidiabetic Drugs
IL293353A (he) טיפול משולב באמצעות קו-אגוניסטים של גלוקאגון ו- glp-1 לטיפול בהשמנה
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
JP2022522461A (ja) 代謝性障害の処置のための組換えタンパク質の使用
HK40083623A (en) Dosing regimen of glp-1
HK40056898A (en) Glp-1 composition for treating obesity and weight management